SCHEMBL2368907

SCHEMBL2368907

Clc1nc(-c2ccco2)c2c(-c3ccccc3)csc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.50
TMIGD3 P0DMS9 1/20 0.43
ADORA1 P30542 1/20 0.43
ALDH1A1 P00352 5/20 0.43
PIK3R1 P27986 2/20 0.43
PIK3CA P42336 2/20 0.43
LMNA P02545 4/20 0.43
HPGD P15428 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CASP3 P42574 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
KMT2A Q03164 4/20 0.42
PKM P14618 3/20 0.40
F2 P00734 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5790688 0.81 ADORA1 (0.50) TMIGD3ADORA1ALDH1A1PIK3R1PIK3CA
SCHEMBL2368759 0.78 BTK (0.39) ESR1TMIGD3ADORA1ALDH1A1PIK3R1
SCHEMBL3382540 0.77 ESR1 (0.47) ESR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL2368408 0.76 LMNA (0.62) ESR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL3382545 0.74 ESR1 (0.71) ESR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL5792440 0.73 HTT (0.59) ALDH1A1LMNAKDM4EMAPTSMN1; SMN2
SCHEMBL5791106 0.68 ALDH1A1 (0.56) ALDH1A1PIK3R1PIK3CALMNAKDM4E
SCHEMBL14965235 0.68 LMNA (0.68) ESR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL31336915 0.67 ALDH1A1 (0.51) ESR1ALDH1A1LMNAHPGDKDM4E
SCHEMBL2899958 0.67 ALDH1A1 (0.51) ESR1ALDH1A1LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ESR1 4494/4885TMIGD3 4357/4885ADORA1 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.